Clinical Trial Update: Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of hyperthermia and Olaparib for breast cancer patients with chest wall recurrences has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma | Phase 1 | Status: TERMINATED